4 completed, 1 withdrawn. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
Follow grazoprevir: new trials by email Literature Review of grazoprevir trials Research Report on grazoprevir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010) Grazoprevir - Hepatitis C | Phase 1 | Completed | Merck Sharp & Dohme LLC | 4 | 2013-10-01 | 2018-09-14 |
| The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) Grazoprevir, Elbasvir - Chronic Hepatitis C, Renal Impairment | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2013-09-06 | 2019-06-12 |
| Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022) Peg-Interferon, Liver Samples from FNA, Liver Samples from CNB - Chronic Hepatitis C | Phase 1 | Withdrawn | Merck Sharp & Dohme LLC | 2012-05-01 | 2015-10-14 | |
| Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013) Grazoprevir - Hepatitis C | Phase 1 | Completed | Merck Sharp & Dohme LLC | 50 | 2011-07-28 | 2018-09-14 |
| A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004) Grazoprevir, Placebo - Hepatitis C | Phase 1 | Completed | Merck Sharp & Dohme LLC | 91 | 2010-02-23 | 2018-07-17 |
Hepatitis C (3) · Hepatitis C, Chronic (2) · Renal Insufficiency (1)
PMID 28947470, PMID 29703432, PMID 30680407
2009 (1)